- Home
- NBTX
NBTX
Nanobiotix S.A.
as 12-20-2024 3:39pm EST
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
| Founded: | 2003 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 201.9M | IPO Year: | 2020 |
| Target Price: | $12.00 | AVG Volume (30 days): | 64.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.76 - $8.96 | Next Earning Date: | 12-31-2024 |
| Revenue: | $45,220,186 | Revenue Growth: | 526.17% |
| Revenue Growth (this year): | -43.4% | Revenue Growth (next year): | -41.26% |
Latest Nanobiotix S.A. News
NBTX Breaking Stock News: Dive into NBTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
GlobeNewswire
11 days ago
Voting Rights and Shares Capital of the Company
MT Newswires
13 days ago
Nanobiotix's NBTXR3 Phase 1 Study Yields Promising Results for Pancreatic Cancer Treatment
GlobeNewswire
13 days ago
NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
GlobeNewswire
a month ago
Voting Rights and Shares Capital of the Company
GlobeNewswire
a month ago
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
GlobeNewswire
2 months ago
NANOBIOTIX to Participate in Multiple Investor Conferences in November
GlobeNewswire
2 months ago
Voting Rights and Shares Capital of the Company
Compare NBTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NBTX Nanobiotix S.A. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.